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Abstract  
BACKGROUND: Previous studies suggested that alterations in serum cortisol and DHEA-S levels 
may play a role in the pathophysiology of schizophrenia.  
AIM: To compare serum cortisol and DHEA-S levels between patients with schizophrenia and 
healthy controls and to evaluate their association with the response to antipsychotic treatment. 
MATERIAL AND METHODS: In this clinical prospective study were included 60 patients with 
schizophrenia and 40 healthy age and sex matched control subjects. Clinical evaluation of patients 
was performed using the Positive and Negative Symptom Scale. A questionnaire for socio-
demographic and clinical data collection was used. For the purposes of the study, the examined 
group was divided in two subgroups: responders and nonresponders. Serum cortisol and DHEA-S 
levels were measured at baseline in all participants and after 3 and 6 weeks of the antipsychotic 
treatment in patients with schizophrenia. 
RESULTS: Patients with schizophrenia had significantly higher serum cortisol and DHEA-S levels 
in comparison to the control group. Responders had significantly higher serum cortisol and DHEA-S 
levels compared with nonresponders. 
CONCLUSION: Elevated serum cortisol and DHEA-S levels may play a role in the pathophysiology 
of schizophrenia and they may be related to positive response to antipsychotic treatment in patients 
with schizophrenia. 
  
 
 
 
 
Introduction 
 
The neuroendocrinologic system, particularly 
the HPA axis, has been a focus of interest for 
neurobiological studies aiming at elucidating the 
cause of schizophrenia [1]. HPA axis abnormalities 
may cause an increase in the baseline cortisol level 
[2]. It has been demonstrated that serum baseline 
cortisol levels are increased in patients with 
schizophrenia [1-10]. However there are also other 
studies with contrary findings [11-12].  
 Recently there has been increased interest in 
the role of dehydroepiadrosterone (DHEA) which, in 
its sulfated form (DHEA-S) is the most abundant in 
humans [13]. It is considered both a neurosteroid, 
being produced in the brain, as well as a neuroactive 
steroid, produced in the adrenals and gonads and 
having its effect on the brain [14]. 
Dehydroepiandrosterone sulfate (DHEA-S) is a 
neuroactive steroid interacting with N-methyl D-
aspartate (NMDA) and gamma-aminobutyric acid 
(GABA) receptors [15]. Also DHEA-S may act as 
endogenous neuroprotective factor. The decline of its 
level during aging and schizophrenia may leave the 
brain unprotected against neurotoxic challenges [16].  
Previous studies investigating DHEA-S blood levels in 
patients with schizophrenia have demonstrated 
elevated DHEA-S levels [2, 17-18], no different [11, 
19] and decreased levels [20] in schizophrenia 
patients compared to healthy controls. The 
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inconsistencies in published findings may be due to 
wide clinical polymorphism, small sample sizes or 
differences in the age and duration of illness of 
patients enrolled in the studies [21]. Authors of one 
study reported elevated serum DHEA-S levels in first 
episode male patients with schizophrenia compared to 
male patients with schizophrenia who were not in the 
first episode but were in a phase of acute 
exacerbation. According to their results they 
suggested that this neurosteroid response is unique to 
first-episode schizophrenia patients [22]. 
 Previous studies have suggested that 
alterations in cortisol and DHEA-S levels may play a 
role in the pathophysiology of schizophrenia [2, 18, 
23-26]. Serum cortisol and DHEA-S levels may be 
used as a biological marker for the diagnosis of 
schizophrenia; however, further studies with larger 
sample sizes are warranted to support this finding [2].  
 Authors of one study investigated association 
between serum cortisol, DHEA-S levels, as well as 
their molar ratios with the response to antipsychotic 
treatment in patients with schizophrenia during the 
exacerbation of the disorder [21]. They suggest that 
imbalance in serum cortisol and DHEA-S may be 
related to pathophysiological processes in 
schizophrenia, particularly to responsivity to 
antipsychotic treatment. 
 The aim of the study was to compare serum 
cortisol and dehydroepiandrosterone-sulfat levels 
between patients with schizophrenia and healthy 
control subjects and to evaluate association between 
these hormones and response to antipsychotic 
treatment in schizophrenic patients.  
 
 
Material and Methods 
  
In this clinical prospective study by its design 
were included 60 patients with schizophrenia and 40 
healthy age and sex matched control subjects.  
 Examined group consisted of sixty patients 
with schizophrenia from both genders; age 18-50, 
treated as inpatients or outpatients at the University 
Clinic of Psychiatry, Skopje, Macedonia. All patients 
experienced an acute exacerbation of the illness 
(PANSS: P1-Delusions and P3-Hallucinatory behavior 
≥ 4). Patients who suffered from major physical 
illness, drug or alcohol abuse, epilepsy and other 
organic brain syndromes were not included. All 
patients underwent physical examination and routine 
laboratory tests to rule out physical illness. Clinical 
evaluation of patients was performed using the 
Positive and Negative Symptom Scale [27]. Non-
standardized questionnaire was used for socio-
demographic and clinical data collection. 
 For the purposes of this study, the examined 
group was divided in two subgroups: 
1. subgroupof subjects suffering from 
schizophrenia classified as responders who 
had no ratings of >3 on items P1, P2, P3, P5 
and P6 of the PANSS; 
2. subgroup of subjects suffering from 
schizophrenia who did not meet these criteria 
were defined as nonresponders. 
 Control group consisted of forty healthy age 
and sex matched control subjects. All were physically 
healthy and had no personal or family history of 
psychiatric illness.  
 All participants in the study provided written 
informed consent to participate in this prospective 
study after having received a detailed explanation of 
the study procedures. The study was approved by the 
Ethics Committee of Medical University in Skopje and 
the Board of the University Clinic of Psychiatry. 
 
Steroid determination 
 Serum cortisol and DHEA-S levels were 
measured in the Institute of clinical biochemistry at the 
Medical University in Skopje. Serum samples of 
cortisol and DHEA-S were collected between 8 a.m. 
and 9 a.m. hours after 20 min of rest. All participants 
were instructed to abstain from unusual physical 
activity or stress for a period of 24 h prior to blood 
sampling. Blood samples were collected at baseline in 
all participants and after 3 and 6 weeks of the 
antipsychotic treatment in patients with schizophrenia. 
Cortisol and DHEA-S levels were measured by the 
IMMULITE 2000, competitive chemiluminescent 
enzime immunoassay. 
 
Statistical analysis 
 Several statistical methods have been used 
for the statistical analysis of the data obtained in the 
course of the study: non-parametric methods (Chi-
square test, Mann-Whitney U test) and parametric 
methods (t-test for independent samples). From the 
multivariate methods MANOVA was used. Values of p 
< 0.05 were considered statistically significant. 
 
 
Results 
  
Patients with schizophrenia had significantly 
higher mean serum cortisol and DHEA-S levels in 
comparison to the control group (Table 1). 
 The two subgroups of the examined group 
classified as  responders  and  nonresponders did not  
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Table 1: Serum levels of cortisol and DHEA-S in the examined 
and control group. 
Hormone  Examined group Control group t-test p-value 
 Cortisol (nmol/L) 555.7 ± 159.8 351.7 ± 172.1 6.07 <0.001 
 DHEA-S (mcg/dL) 3295 ± 125.1 167.4 ± 57.5 7.66 <0.001 
 (t-test for independent samples)   
 
significantly differ between themselves in terms of 
gender (men/women: 29/8 and 15/8 respectively; 
Pearson Chi-square =1.26, df = 1, p = 0.26), age (t = 
0.34, p = 0.73), marital status (Pearson Chi-square = 
1.41, df = 2, p = 0.49), education (Pearson Chi-square 
= 4.21, df = 3, p = 0.24), age of onset of the disorder 
(Z = 0.15, p = 0.88), duration of illness (Z = 0.32, p = 
0.75), number of relapses (Z = 0.11, p = 0.9), number 
of hospital treatments (Z = 0.68, p = 0.49) and the 
type of antipsychotic agents - typical/atypical (Pearson 
Chi-square = 0.86, df =1, p = 0.35). 
 Graph 1 shows serum cortisol and DHEA-S 
levels in the subgroup of responders compared with 
the subgroup of nonresponders at baseline 
assessment point. 
 
Figure 1: Serum cortisol (nmol/L) and DHEA-S (mcg/dL) levels at 
baseline in responders and nonresponders. 
 
 
 Table 2 shows mean serum cortisol and 
DHEA-S values after 3 and 6 weeks of antipsychotic 
therapy in responders and nonresponders.  
Тable 2: Serum cortisol and DHEA-S levels after 3 and 6 weeks 
of antipsychotic therapy in responders and nonresponders. 
Hormone Responders 
N=37 
Nonresponders 
N=23 
After 3 weeks 
Cortisol  (nmol/L) 530.9 ± 133.1 404.6 ± 119.2 
DHEA-S (mcg/dL) 339.2 ± 132.9 239.9 ± 113.8 
After 6 weeks 
Cortisol (nmol/L) 449.9 ± 147.2 325.4 ± 125.1 
DHEA-S (mcg/dL) 303.9 ± 121.0 224.9 ± 108.1 
 
 
 Across all three assessment points (baseline, 
after 3 and 6 weeks) the responders had a 
significantly higher serum cortisol and DHEA-S levels 
compared with nonresponders. Hormonal values 
significantly decrease during the study period of 6 
weeks in both subgroups. Significant 'group' x 'time' 
interaction was found for hormone cortisol (p=0.002) 
(Table 3). 
Таble 3: Comparison of hormonal concentrations between 
responders and nonresponders across three points 
(MANOVA). 
Serum stress 
hormones 
t-value Df F p 
Responders vs non-responders 
Hotelling-Lawley test 0.62 3            56 11.46 <0,001 
Cortisol 1054548.030 1            58 28.683 <0001 
DHEA-S 366603.017 1            58 10.747 0.002 
Across three examination 
Hotelling-Lawley test 0.862 6           226 16.24 <0.001 
Cortisol 576305.421 2           116 44.38 <0.001 
DHEA-S 77337.031 2           116 10.08 <0.001 
Interaction 
Hotelling-Lawley test 0.147 6           226 2.77 0.013 
Cortisol 87261.088 2           116 6.72 0.002 
DHEA-S 16020.123 2           116 2.09 0.13 
 
 
 
Discussion 
  
Recently, studies on schizophrenia have 
increasingly focused on potential causative factors, 
such as structural and functional brain abnormalities. 
The assumption that alterations in cortisol and DHEA-
S levels may have a role in changes in clinical 
presentation of several neuropsychiatric disorders, 
including schizophrenia, has been emphasized [2]. 
 Our study showed that plasma cortisol levels 
were significantly elevated in the group of patients 
with schizophrenia compared with controls, which is in 
agreement with the results of most of the studies [1-
10]. However there are studies reporting no significant 
differences between the schizophrenic patients and 
healthy controls in terms of cortisol levels [11, 28], as 
well as lower cortisol levels in patients with 
schizophrenia [12]. 
 Examined serum DHEA-S levels in this study 
showed statistically significant higher levels in patients 
with schizophrenia compared to control subjects, 
which coincided with the results of most of the studies 
[2, 17-18]. In contrast, some other studies found 
decreased serum DHEA-S levels [20] and no different 
[11] in schizophrenia patients compared to healthy 
controls. 
 According to our results we can conclude that 
elevated serum cortisol and DHEA-S levels in patients 
with schizophrenia may play a role in the 
pathophysiology of schizophrenia and they may be 
used as a biological marker for the diagnosis of 
schizophrenia.   
 The present study also evaluated association 
between serum cortisol and DHEA-S levels and 
response to antipsychotic treatment in patients with 
schizophrenia. At baseline assessment point the 
subgroup of responders showed significantly higher 
serum cortisol and DHEA-S levels compared with the 
subgroup of nonresponders. Across all three 
assessment points the responders had a significantly 
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higher serum cortisol and DHEA-S levels compared 
with nonresponders which is in agreement with the 
results of other study [21]. Our results suggest that 
elevated serum cortisol and DHEA-S levels may be 
related to positive response to antipsychotic treatment 
in patients with schizophrenia.  
 Higher serum cortisol and DHEA-S levels 
among responders compared with nonresponders 
may be explained by the differences in symptom 
severity on PANSS factors across three examination 
points. Our study showed that responders scored 
significantly higher on positive PANSS scale, 
delusions and suspiciousness compared with 
nonresponders which coincided with the results of 
other study [21]. Responders also showed greater 
reduction of the PANSS positive and negative scale 
scores across all three assessment points compared 
with nonresponders. 
 Future studies that examine serum cortisol 
and DHEA-S levels before and after the 
dexamethasone administration are needed to 
disentangle the baseline and feedback components of 
the HPA axis alteration in patients with schizophrenia.  
 
Conclusions 
 Serum cortisol and DHEA-S levels were 
significantly elevated in the group of patients with 
schizophrenia compared with healthy controls. 
 Elevated serum cortisol and DHEA-S levels 
may be used as a biological marker for the diagnosis 
of schizophrenia. 
 The subgroup of responders had a 
significantly higher serum cortisol and DHEA-S levels 
compared with the subgroup of nonresponders. 
 Elevated serum cortisol and DHEA-S levels 
may be related to positive response to antipsychotic 
treatment in patients with schizophrenia. 
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